R-1663

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C24H21ClF3N5O3
Molecular Weight	519.903
Optical Activity	UNSPECIFIED
Defined Stereocenters	2 / 2
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

FC(F)CN1C[C@@H]([C@H](C1)C(=O)NC2=CC=C(C=C2F)N3C=CC=CC3=O)C(=O)NC4=NC=C(Cl)C=C4

InChI

InChIKey=DVMCMTVFXINJGW-IRXDYDNUSA-N

InChI=1S/C24H21ClF3N5O3/c25-14-4-7-21(29-10-14)31-24(36)17-12-32(13-20(27)28)11-16(17)23(35)30-19-6-5-15(9-18(19)26)33-8-2-1-3-22(33)34/h1-10,16-17,20H,11-13H2,(H,30,35)(H,29,31,36)/t16-,17-/m0/s1

HIDE SMILES / InChI

Molecular Formula	C24H21ClF3N5O3
Molecular Weight	519.903
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	2 / 2
E/Z Centers	0
Optical Activity	UNSPECIFIED

Approval Year

Substance Class	Chemical Created by `admin` on `Tue Apr 01 16:28:37 GMT 2025` Edited by `admin` on `Tue Apr 01 16:28:37 GMT 2025`
Record UNII	H5XZ7LKC6C
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

R-1663

Code

English

R1663

Preferred Name

English

3,4-PYRROLIDINEDICARBOXAMIDE, N-(5-CHLORO-2-PYRIDINYL)-1-(2,2-DIFLUOROETHYL)-N'-(2-FLUORO-4-(2-OXO-1(2H)-PYRIDINYL)PHENYL)-, (3R,4R)-

Systematic Name

English

(3R,4R)-N3-(5-CHLORO-2-PYRIDYL)-1-(2,2-DIFLUOROETHYL)-N4-(2-FLUORO-4-(2-OXO-1-PYRIDYL)PHENYL)PYRROLIDINE-3,4-DICARBOXAMIDE

Systematic Name

English

(2R,4R)-N1-(4-CHLOROPHENYL)-4-HYDROXY-N2-(4-(3-OXOMORPHOLINO)PHENYL)PYRROLIDINE-1,2-DICARBOXAMIDE

Systematic Name

English

Code System Code Type Description

FDA UNII

H5XZ7LKC6C

Created by admin on Tue Apr 01 16:28:37 GMT 2025 , Edited by admin on Tue Apr 01 16:28:37 GMT 2025

PRIMARY

PUBCHEM

24849206

Created by admin on Tue Apr 01 16:28:37 GMT 2025 , Edited by admin on Tue Apr 01 16:28:37 GMT 2025

PRIMARY

CAS

865451-66-7

Created by admin on Tue Apr 01 16:28:37 GMT 2025 , Edited by admin on Tue Apr 01 16:28:37 GMT 2025

PRIMARY

Related Record Type Details


					HYF6HN9XGQ

FACTOR XA

TARGET -> INHIBITOR

Qualification:

Ki

Amount:

Related Record Type Details


					H5XZ7LKC6C

R-1663

ACTIVE MOIETY

Comments:

R1663 doses up to 300 mg twice daily or 400 mg once daily were administered for seven days. The exploration of gender and age effect was carried out in separate cohorts of eight male and eight female volunteers aged 45 to 65 years. Multiple oral doses of R1663 were safe and well tolerated. Pharmacokinetics was linear and showed moderate variability. Plasma concentrations peaked at 3 hour. Terminal half-life at steady state was 3-5 hours. Accumulation of R1663 was minimal. R1663 prolonged clotting times, inhibited thrombin generation (peak height and endogenous thrombin potential (ETP)) and anti-factor Xa activity in a concentration-dependent manner without increasing bleeding time. Pharmacodynamic parameters were strongly correlated to R1663 plasma concentrations. The inhibition was more pronounced on peak height (IC50 = 194 ng/ml) than on ETP (2790 ng/ml). Pharmacokinetics and pharmacodynamics of R1663 appeared not to be substantially affected by age or gender but remained to be confirmed in larger clinical trials including older patients.

Amount:


					H5XZ7LKC6C

R-1663

ACTIVE MOIETY

Comments:

Class: Anticoagulant, Antithrombotic, Small molecule; Mechanism of Action: Factor Xa inhibitor; Highest Development Phase: Phase I for Thrombosis; Most Recent Events: 28 Aug 2012 Roche completes a phase I trial in Healthy volunteers in United Kingdom, 03 May 2012 Roche completes a phase I trial in Healthy volunteers in United Kingdom, 03 May 2012 Phase-I clinical trials in Thrombosis (in volunteers) in United Kingdom (PO)

Amount:


					H5XZ7LKC6C

R-1663

ACTIVE MOIETY

Comments:

AIMS: To explore the effect of food intake on the relative bioavailability of R1663 and on its pharmacodynamic effects (prothrombin time (PT) and activated partial thromboplastin time (aPTT)) after a single oral dose of 200 mg. RESULTS: Following food intake, C(max) was reduced by 10% with CI extended outside the bioequivalence range (GMR, 0.90 CI 0.72 - 1.13). R1663 t(max) was delayed in the fed state (4 h) as compared to the fasted state (1 h). There was no significant food effect on R1663 AUC(0-) (GMR, 1.09 CI 0.97 - 1.24). Although the Emax of PT showed statistically significant reduction with food, the 90% CIs for Emax and AUE(0-48) of PT and aPTT were all contained within the bioequivalence range (0.80 - 1.25).

Amount: